Dutasteride
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Dutasteride
- Dutasteride: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
Using the txgnn-pipeline skill confirmed no additional formatting rules apply beyond the report template already provided — proceeding to generate the report directly from the Evidence Pack.
Dutasteride: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Dutasteride is a dual 5α-reductase inhibitor, internationally used to treat benign prostatic hyperplasia (BPH) by lowering dihydrotestosterone (DHT) levels. The TxGNN model’s highest-scoring candidate indication is Ambras type hypertrichosis universalis congenita, a rare congenital hair-overgrowth disorder, but this prediction is currently supported by zero clinical trials and zero published literature, and the model’s own rationale flags the underlying mechanism as a poor biological fit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the SAHPRA registry (Dutasteride is not currently marketed in South Africa); internationally approved for benign prostatic hyperplasia |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (drugbank field flagged as a data gap). Based on what is embedded in the evidence pack’s own repurposing rationale, Dutasteride acts as a dual 5α-reductase inhibitor that lowers DHT — the mechanism underlying its efficacy in androgen-driven conditions such as BPH and androgenetic alopecia.
Ambras type hypertrichosis universalis congenita, however, is a rare congenital disorder caused by a chromosomal rearrangement at 8q24, producing generalised excess hair growth through a developmental pathway that is not androgen-dependent. The evidence pack’s own mechanistic assessment explicitly notes this mismatch: even though “reducing hair growth” might superficially seem relevant to a hypertrichosis diagnosis, the disease’s actual biology does not run through the DHT/5α-reductase axis that Dutasteride targets, so there is no established pharmacological basis for benefit.
A further caution: this candidate’s TxGNN score (99.998%) sits at overall model rank 50, and eight of the ten candidates in this evidence pack cluster in a similarly narrow, near-ceiling score band (99.56%–99.998%, ranks 50–2604) with no supporting trials or literature. This pattern is consistent with score saturation/embedding-proximity noise rather than a strong, discriminative therapeutic signal, and should be weighted accordingly when interpreting the ranking.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Dutasteride currently holds no SAHPRA product registrations and is recorded as not marketed in South Africa in this evidence pack (0 licenses on file). No product-level dosage form or approved-indication data is therefore available from the local registry.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: this evidence pack flags SAHPRA/local warning and contraindication data as a Blocking data gap (DG001) — meaning a preliminary safety screen (S1) cannot be completed until this information is obtained.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The candidate indication is supported only by TxGNN’s model score (Evidence Level L5) — there are no clinical trials and no literature of any kind.
- The evidence pack’s own mechanistic analysis indicates the drug’s DHT-lowering action does not plausibly address the non-androgen-dependent, chromosomally driven pathology of Ambras type hypertrichosis.
- A Blocking data gap (missing SAHPRA/TFDA warnings and contraindications) prevents even an initial safety assessment (S1) from being started.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, precautions, contraindications) — currently a Blocking gap (DG001)
- Confirmed mechanism-of-action data from DrugBank/primary sources — currently a High-severity gap (DG002)
- Preclinical or mechanistic evidence directly linking the 5α-reductase/DHT pathway to Ambras type hypertrichosis pathophysiology
- Clarification of whether pharmacological suppression of hair growth is even a clinically desired outcome for this congenital condition, as the current rationale itself is conditional (“if needed”)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.